Cronin K A, Feuer E J
Applied Research Branch, National Cancer Institute, EPN 4103, 6130 Executive Boulevard, Bethesda, MD 20892, USA.
Stat Med. 2000 Jul 15;19(13):1729-40. doi: 10.1002/1097-0258(20000715)19:13<1729::aid-sim484>3.0.co;2-9.
A common population-based cancer progress measure for net survival (survival in the absence of other causes) of cancer patients is relative survival. Relative survival is defined as the ratio of a population of observed survivors in a cohort of cancer patients to the proportion of expected survivors in a comparable set of cancer-free individuals in the general public, thus giving a measure of excess mortality due to cancer. Relative survival was originally designed to address the question of whether or not there is evidence that patients have been cured. It has proven to be a useful survival measure in several areas, including the evaluation of cancer control efforts and the application of cure models. However, it is not representative of the actual survival patterns observed in a cohort of cancer patients. This paper suggests a measure for cumulative crude (in the presence of other causes) cause-specific probability of death for a population diagnosed with cancer. The measure does not use cause of death information which can be unreliable for population cancer registries. Point estimates and variances are derived for crude cause-specific probability of death using relative survival instead of cause of death information. Examples are given for men diagnosed with localized prostate cancer over the age of 70 and women diagnosed with regional breast cancer using Surveillance, Epidemiology and End Results (SEER) Program data. The examples emphasize the differences in crude and net mortality measures and suggest areas where a crude measure is more informative. Estimates of this type are especially important for older patients as new screening modalities detect cancers earlier and choice of treatment or even 'watchful waiting' become viable options. Published in 2000 by John Wiley & Sons, Ltd.
一种常用于衡量癌症患者净生存(无其他死因情况下的生存)情况的基于人群的癌症进展指标是相对生存。相对生存定义为癌症患者队列中观察到的幸存者数量与普通人群中一组可比的无癌个体预期幸存者比例之比,从而给出因癌症导致的额外死亡率的一种衡量方法。相对生存最初旨在解决是否有证据表明患者已治愈的问题。它已被证明在多个领域是一种有用的生存指标,包括癌症控制效果评估和治愈模型的应用。然而,它并不代表癌症患者队列中实际观察到的生存模式。本文提出了一种针对被诊断患有癌症的人群的累积粗(存在其他死因情况下)特定病因死亡概率的衡量方法。该衡量方法不使用可能对人群癌症登记处不可靠的死亡原因信息。使用相对生存而非死亡原因信息来推导粗特定病因死亡概率的点估计值和方差。利用监测、流行病学和最终结果(SEER)计划数据,给出了70岁以上被诊断患有局限性前列腺癌的男性和被诊断患有区域性乳腺癌的女性的示例。这些示例强调了粗死亡率和净死亡率衡量方法的差异,并指出了粗衡量方法更具信息性的领域。对于老年患者而言,此类估计尤为重要,因为新的筛查方式能更早地检测出癌症,治疗选择甚至“观察等待”都成为可行的选项。由约翰·威利父子有限公司于2000年出版。